Q-omics provides the consensus-scored RANGRF profile across patient tissues and cancer cell-line models. RANGRF expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, RANGRF is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, RANGRF RNA expression shows 18,408 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SCLC, HNSC, and THYM as cancer lineages where RANGRF shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RANGRF — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RANGRF survival associations across molecular data types. RANGRF RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RANGRF RNA expression–survival associations across cancer types. High RANGRF expression shows unfavorable associations in KIRC and UCS, but favorable associations in SCLC, UCEC, PAAD and LUAD. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for RANGRF RNA expression.
This table summarizes RANGRF tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RANGRF. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RANGRF shows lower tumor expression in KIRC, KICH and LUSC and higher tumor expression in HNSC, THCA and LIHC. The HNSC box plot shows higher RANGRF RNA expression in tumor versus normal tissue (log2 FC = +0.974, t-test p < 0.001).
This table shows molecular features associated with RANGRF in patient tissues and cancer cell lines. In patient samples, RANGRF shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RANGRF RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
